BeiGene Advances R/R CLL/SLL Treatment with FDA Fast-Tracked BGB-16673 in Phase I/II Clinical Trial
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company, has been granted Fast...
MicroPort Endovascular MedTech Reports 26.63% YOY Revenue Growth and Strong R&D Investment in 2024H1
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese endovascular device manufacturer, has reported...
Shanghai Pharmaceuticals Posts 5.14% YOY Revenue Growth in 2024H1 with Focus on Cell Therapies
Shanghai Pharmaceuticals Holding Co. (SPH; HKG: 2607; SHA: 601607) has announced its financial results for...
Innovent Biologics’ President Liu Yongjun Resigns, CEO De-Chao Micheal Yu Takes R&D Reins
Innovent Biologics Inc., a leading biopharmaceutical company based in China and listed on the Hong...
Fosun Pharma’s Privatization of Henlius Includes Cash and Share Offers, Aims for Full Equity Control
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...
China’s CDE Approves Multitude Therapeutics’ AMT-676 for Clinical Study in Solid Tumors
The Center for Drug Evaluation (CDE) of China has granted clinical study approval for Multitude...
Chinese NMPA Grants License to MicroPort Endovascular MedTech’s Venous Stent for Treating Vascular Conditions
Shanghai MicroPort Endovascular MedTech Co., Ltd, a Chinese endovascular device manufacturer listed on the Shanghai...
Mabwell Bioscience Initiates Phase III Trial for 9MW2821 Combo in Urothelial Carcinoma Following NMPA Clearance
Mabwell (Shanghai) Bioscience Co., Ltd, a biopharmaceutical company listed in China (SHA: 688062), has announced...
CStone Pharmaceuticals Reports 2024 Interim Results with Strategic Collaborations and Regulatory Milestones
CStone Pharmaceuticals, a biopharmaceutical company based in China and listed on the Hong Kong Stock...
Suzhou-Based Medical Device Innovator Ensurge Secures RMB 100 Million in Latest Financing Round
Ensurge, a cutting-edge medical device manufacturer headquartered in Suzhou, is reportedly in the spotlight for...
US FDA Approves Updated COVID-19 mRNA Vaccines from Pfizer/BioNTech and Moderna Ahead of Winter
The U.S. Food and Drug Administration (FDA) has granted approval to two updated mRNA COVID-19...
Guangzhou-Based Bio-Thera Solutions Expands Market Presence with Biosimilars and Innovative Drug Approvals
Bio-Thera Solutions, a biotech company based in Guangzhou and listed on the Shanghai Stock Exchange...
National Healthcare Security Administration Reports Pricing Revisions on Aortic Stent Grafts by Major Manufacturers
The National Healthcare Security Administration (NHSA) has reported that 12 device manufacturers, both domestic and...
Shouyao Holdings Receives Clinical Trial Approval for SY-7166 in Treating Multiple Myeloma
Shouyao Holdings (Beijing) Co., Ltd, a biopharmaceutical company headquartered in Beijing and listed on the...
Takeda Prepares to File Dengue Fever Vaccine for US Approval, Expanding Global Regulatory Reach
Takeda Pharmaceutical, a leading Japanese pharmaceutical company listed on the NYSE (NYSE: TAK), is reportedly...
China to Enhance Basic Medical Insurance Coverage for Residents in 2024 with Increased Subsidies and Personal Payments
The National Healthcare Security Administration (NHSA), in conjunction with the Ministry of Finance and State...
Henlius Biotech’s Biosimilar Herceptin Approved by Health Canada for Breast and Gastric Cancer Treatments
Shanghai Henlius Biotech Inc., a leading biopharmaceutical company based in China and listed on the...
Jiangsu Simcere Pharmaceutical Gets NMPA Green Light for SIM0508 Clinical Trial in Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2096),...
Mabwell Bioscience Receives Approval for Phase III Trial of 9MW2821 in Cervical Cancer from China’s CDE
Mabwell (Shanghai) Bioscience Co., Ltd, a biopharmaceutical company listed in China (SHA: 688062), has received...
ImmuneOnco Receives USD 10 Million Upfront Payment from Instil Bio Subsidiary for Licensing Deal
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has received a USD 10 million upfront payment...